Last checked at 
(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
Angle said a key focus during Downing Street's lockdown had been finalising a significant amount of written documentation and analysis for its imminent submission to the US Food and Drug Administration.
The AIM-listed firm stated it had a cash runway that took it out to mid-2021 and noted that it had received a ?1.9m research and development tax credit, was managing its resources and had furloughed staff.
At Angle's Toronto-based labs, HyCEAD Ziplex analytical and assay verification work for its ovarian cancer test was said to be "progressing".
Elsewhere, Angle said Parsotix, its liquid biopsy system, had the potential to help guide trials in future waves of cancer immunotherapies.
Angle said cancer studies would benefit immensely from biomarker technology like Parsotix as it would help assess just which patient was likely to respond to certain drug candidates.
As of 1000 BST, Angle shares were down 5.11% at 65p.
28 Sep 2020 19:33
IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix
IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix
Read more